{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:09:22Z","timestamp":1793351362836,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.vaccine.2011.06.094","type":"journal-article","created":{"date-parts":[[2011,7,20]],"date-time":"2011-07-20T01:52:26Z","timestamp":1311126746000},"page":"7229-7241","source":"Crossref","is-referenced-by-count":273,"title":["From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine"],"prefix":"10.1016","volume":"29","author":[{"given":"Bruno","family":"Guy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Barrere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Malinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remy","family":"Teyssou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.06.094_bib0005","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"Suppl 12","author":"Guzman","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2011.06.094_bib0015","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0020","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0025","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0030","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2011.06.094_bib0035","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.6.9.12739","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine","volume":"6","author":"Guy","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0040","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"8","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0045","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.vaccine.2006.06.082","article-title":"High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production","volume":"25","author":"Barban","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0050","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/JVI.78.2.1032-1038.2004","article-title":"High fidelity of yellow fever virus RNA polymerase","volume":"78","author":"Pugachev","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0400","doi-asserted-by":"crossref","unstructured":"Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, et al., Genetic stability of a dengue vaccine based on chimeric yellow fever\/dengue viruses. Vaccine 2011, in press, doi:10.1016\/j.vaccine.2011.06.101.","DOI":"10.1016\/j.vaccine.2011.06.101"},{"issue":"7","key":"10.1016\/j.vaccine.2011.06.094_bib0055","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1073\/pnas.84.7.2019","article-title":"Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it","volume":"84","author":"Hahn","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0060","first-page":"227","article-title":"Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice","volume":"32","author":"Miller","year":"1988","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0065","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/JVI.76.12.6172-6184.2002","article-title":"Neuroblastma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread","volume":"76","author":"Vlaycheva","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2005.03.009","article-title":"Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys","volume":"33","author":"Monath","year":"2005","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0075","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/77553","article-title":"Human skin Langerhans cells are targets of dengue virus infection","volume":"6","author":"Wu","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0080","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/JVI.75.8.3501-3508.2001","article-title":"Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis","volume":"75","author":"Libraty","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0085","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/JVI.79.4.2432-2439.2005","article-title":"Differential effects of dengue virus on infected and bystander dendritic cells","volume":"79","author":"Palmer","year":"2005","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.06.094_bib0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1086\/596507","article-title":"Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection","volume":"199","author":"Long","year":"2009","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2011.06.094_bib0095","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1128\/JVI.01224-10","article-title":"The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults","volume":"84","author":"Hoang","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4269\/ajtmh.2005.72.74","article-title":"Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells","volume":"72","author":"Brandler","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4269\/ajtmh.2007.76.144","article-title":"Innate immune responses in human dendritic cells upon infection by chimeric Yellow fever Dengue vaccines serotype 1 to 4","volume":"76","author":"Deauvieau","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jiq022","article-title":"Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1\u20134 vaccine virus strains","volume":"203","author":"Balas","year":"2011","journal-title":"J Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2011.06.094_bib0115","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1128\/JVI.01694-06","article-title":"TRAIL is a novel antiviral protein against dengue virus","volume":"82","author":"Warke","year":"2008","journal-title":"J Virol"},{"issue":"7322","key":"10.1016\/j.vaccine.2011.06.094_bib0125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature09489","article-title":"2\u2032-O methylation of the viral mRNA cap evades host restriction by IFIT family members","volume":"468","author":"Daffis","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0130","doi-asserted-by":"crossref","first-page":"e926","DOI":"10.1371\/journal.pntd.0000926","article-title":"RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection","volume":"5","author":"Nasirudeen","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2011.06.094_bib0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2011.06.094_bib0140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.immuni.2010.10.006","article-title":"Systems vaccinology","volume":"33","author":"Pulendran","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/315215","article-title":"Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity","volume":"181","author":"Vaughn","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0155","unstructured":"WHO TRS 932 Guideline for the production and quality control of candidate tetravalent dengue vaccines (live); 2003."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0160","unstructured":"USP <1041> Biologics."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0165","unstructured":"Ph. Eur. 0153 Vaccine for Human Use."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0170","unstructured":"EMA\/CHMP\/VWP\/141697\/2009 Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0175","unstructured":"W HO TRS 878 Requirements for the use of animal cells as in vitro substrate for the production of biologicals."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0180","unstructured":"FDA guidance for industry \u2013 characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications; 2010."},{"issue":"2","key":"10.1016\/j.vaccine.2011.06.094_bib0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"issue":"45","key":"10.1016\/j.vaccine.2011.06.094_bib0190","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"issue":"4113","key":"10.1016\/j.vaccine.2011.06.094_bib0195","first-page":"4119","article-title":"Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Summary of a WHO technical consultation","volume":"26","author":"Edelman","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0205","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0210","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0215","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in mexico city: randomized controlled phase 1 trial of safety and immunogenicity","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"22","key":"10.1016\/j.vaccine.2011.06.094_bib0220","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0225","doi-asserted-by":"crossref","unstructured":"Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity and Safety of a Tetravalent Dengue Vaccine in Humans. Am J Trop Med Hyg 2011; in press.","DOI":"10.4269\/ajtmh.2011.10-0436"},{"issue":"3","key":"10.1016\/j.vaccine.2011.06.094_bib0230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/jiq059","article-title":"Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic","volume":"203","author":"Durbin","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0235","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.qco.0000244047.31135.fa","article-title":"Immunopathological mechanisms in dengue and dengue hemorrhagic fever","volume":"19","author":"Green","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0240","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/340822","article-title":"Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren","volume":"185","author":"Mangada","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0245","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.4049\/jimmunol.175.4.2676","article-title":"Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes","volume":"175","author":"Mangada","year":"2005","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2011.06.094_bib0405","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/infdis\/jir012","article-title":"Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection","volume":"203","author":"Hatch","year":"2011","journal-title":"J Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2011.06.094_bib0410","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1016\/j.vaccine.2011.03.038","article-title":"A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness","volume":"29","author":"Gunther","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0260","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nm887","article-title":"Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever","volume":"9","author":"Mongkolsapaya","year":"2003","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2011.06.094_bib0265","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.4049\/jimmunol.0903262","article-title":"Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue","volume":"184","author":"Dung","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0270","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.vaccine.2008.10.086","article-title":"Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development","volume":"27","author":"Thomas","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0275","unstructured":"Galan F, Forrat R, Zambrano B, Bouckenooghe A, Lang J, Dayan G. Priming effect of previous Japanese encephalitis vaccination on humoral immune response to tetravalent dengue vaccine. Presented at: American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3\u20137, 2010."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0280","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4269\/ajtmh.2006.75.986","article-title":"Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand","volume":"75","author":"Higgs","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0285","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(04)16459-3","article-title":"Live flavivirus vaccines: reasons for caution","volume":"363","author":"Seligman","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0290","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(04)16800-1","article-title":"Arguments for live flavivirus vaccines","volume":"364","author":"Hombach","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0295","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1016\/j.vaccine.2004.11.069","article-title":"Recombination and flavivirus vaccines: a commentary","volume":"23","author":"Monath","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0300","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/JVI.01063-09","article-title":"A trans-complementing recombination trap demonstrates a low propensity of flaviviruses for intermolecular recombination","volume":"84","author":"Taucher","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0305","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/527329","article-title":"Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates","volume":"197","author":"McGee","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0310","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/527328","article-title":"Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes","volume":"197","author":"McGee","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0315","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0320","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4269\/ajtmh.1989.40.444","article-title":"Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever","volume":"40","author":"Kliks","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0325","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.vaccine.2004.03.042","article-title":"Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine","volume":"22","author":"Guy","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0330","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0335","unstructured":"Lefeuvre A. Caract\u00e9risation des interactions entre les cellules h\u00e9patiques et les souches sauvage et vaccinale du virus de la fi\u00e8vre jaune: application \u00e0 l\u2019\u00e9tude de virus fi\u00e8vre jaune chim\u00e9riques utilis\u00e9s pour le d\u00e9veloppement d\u2019un vaccin contre la dengue. Dipl\u00f4me de Doctorat 2005; Universit\u00e9 Claude Bernard Lyon 1, No 129; 2005."},{"key":"10.1016\/j.vaccine.2011.06.094_bib0340","unstructured":"Barban V, Mantel M, Gulia S, Girerd Y, Boaz M, Crevat D, et al. Evaluation of neutralizing antibody responses against a large range of wild-type isolates in sera of primates vaccinated with CYD TV DEN vaccine. 58th ASTM&H annual meeting Washington DC, Nov 2009. Abstract No 394."},{"issue":"11","key":"10.1016\/j.vaccine.2011.06.094_bib0345","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1371\/journal.pntd.0000890","article-title":"Asia-pacific and Americas dengue prevention boards surveillance working group. best practices in dengue surveillance: a report from the Asia-pacific and Americas dengue prevention boards","volume":"4","author":"Beatty","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2011.06.094_bib0350","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1371\/journal.pntd.0000633","article-title":"High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data","volume":"4","author":"Standish","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0355","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4269\/ajtmh.2008.79.123","article-title":"Epidemiological and clinical observations on patients with dengue in Puerto Rico: results from the first year of enhanced surveillance \u2013 June 2005\u2013May 2006","volume":"79","author":"Ramos","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.vaccine.2011.06.094_bib0360","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.trstmh.2010.06.003","article-title":"A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam","volume":"104","author":"Tien","year":"2010","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.06.094_bib0365","unstructured":"Suaya JA, Shepard DS, Beatty ME. Dengue: burden of disease and costs of illness. Working paper for the Scientific Working Group on Dengue Research, convened by the Special Programme for Research and Training in Tropical Diseases, Geneva, 1\u20135 October 2006. http:\/\/www.tropika.net\/review\/061001Dengue_Burden_of_disease\/article.pdf."},{"issue":"11","key":"10.1016\/j.vaccine.2011.06.094_bib0370","doi-asserted-by":"crossref","first-page":"e903","DOI":"10.1371\/journal.pntd.0000903","article-title":"Dengue incidence in urban and rural cambodia: results from population-based active Fever surveillance, 2006\u20132008","volume":"4","author":"Vong","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2011.06.094_bib0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/648592","article-title":"Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua","volume":"201","author":"Balmaseda","year":"2010","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2011.06.094_bib0380","doi-asserted-by":"crossref","first-page":"e1000139","DOI":"10.1371\/journal.pmed.1000139","article-title":"The impact of the demographic transition on dengue in Thailand: insights from a statistical analysis and mathematical modeling","volume":"6","author":"Cummings","year":"2009","journal-title":"PLoS Med"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2011.06.094_bib0385","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0264-410X(98)00246-1","article-title":"The introduction of new vaccines into developing countries","volume":"17","author":"Mahoney","year":"1999","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2011.06.094_bib0390","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.vaccine.2009.12.035","article-title":"Dengue v2V \u2013 new global initiative supporting transition from vaccine to vaccination","volume":"28","author":"Lam","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2011.06.094_bib0395","doi-asserted-by":"crossref","first-page":"e1000418","DOI":"10.1371\/journal.pmed.1000418","article-title":"Dengue vaccines regulatory pathways: a report on two meetings with regulators of developing countries","volume":"8","author":"Mahoney","year":"2011","journal-title":"PLoS Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11009881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11009881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T12:29:42Z","timestamp":1592742582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11009881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":80,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0264410X11009881"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.06.094","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}